Abstract 578P
Background
This study aimed to describe efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for elderly patients (≥65 years) with treatment-naïve EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Methods
Patients with treatment-naïve EGFR-mutated advanced NSCLC were enrolled at several hospitals in Taiwan between May 2014 and January 2018. Patient characteristics, including age, sex, performance status (PS), smoking history, tumor morphology, mutation type, stage, metastasis, efficacy and safety of EGFR-TKIs were compared. Univariate and multivariate analyses were performed to explore possible prognostic factors.
Results
This study enrolled 1,343 patients with treatment-naïve EGFR-mutated advanced NSCLC, of which 554 were aged <65 years, 383 were aged 65–74 years, 323 were aged 75–84 years, and 83 were aged ≥85 years. In elderly patients, afatinib showed significantly better efficacy, with a median progression-free survival (PFS) of 14.7 months and overall survival (OS) of 22.2 months, than gefitinib (9.9 months and 17.7 months, respectively) and erlotinib (10.8 months and 18.5 months, respectively; PFS: p=0.003; OS: p=0.026). However, patients treated with afatinib also experienced more grade ≥3 adverse events than those treated with gefitinib and erlotinib, including skin toxicities (6.1% vs. 1.8% vs. 3.9%, p=0.052), paronychia (5.1% vs. 0.5% vs. 2.3%, p=0.006), mucositis (1.9% vs. 0% vs. 1.1%, p=0.122), and diarrhea (9.3% vs. 2.3% vs. 1.5%, p<0.0001). PS of 2-4, stage IV disease, liver, bone, pleura, adrenal, and pericardial metastases, and EGFR-TKI treatment with gefitinib were associated with poor PFS, while age of ≥ 85 years, PS of 2-4, stage IV disease, liver, brain, bone, pleura, adrenal, and pericardial metastases, and EGFR-TKI treatment with gefitinib were associated with poor OS. These factors were independent prognostic factors for both PFS and OS.
Conclusions
For elderly patients with EGFR-mutated advanced NSCLC, afatinib was associated with better efficacy than gefitinib or erlotinib in elderly patients with EGFR-mutated advanced NSCLC as a first-line treatment with acceptable AEs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract